Evidence map›Paper›PMID 30312503›Full record

ReviewPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2019

Pediatric asthma: An unmet need for more effective, focused treatments.

Nikolaos G Papadopoulos, Adnan Čustović, Michael D Cabana, Sharon D Dell, Antoine Deschildre, Gunilla Hedlin, Elham Hossny, Peter Le Souëf, Paolo M Matricardi, Antonio Nieto and 6 more

Open access · hybridAbstract readReview
In one paragraph

Review in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 77 citations in OpenAlex.

  1. The evolution of scientific knowledge in childhood asthma over time.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Epidemiology of Childhood Asthma in the UK.Journal of asthma and allergy · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 13 countries.

Nikolaos G PapadopoulosDivision of Infection, Inflammation & Respiratory Medicine, The University of Manchester, Manchester, UK.ORCID 0000-0002-4448-3468
Adnan ČustovićDepartment of Paediatrics, Imperial College London, London, UK.
Michael D CabanaDepartments of Pediatrics and Epidemiology and Biostatistics, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, California.
Sharon D DellDivision of Respiratory Medicine, Department of Pediatrics, Child Health Evaluative Sciences, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Antoine DeschildreCHU Lille, Pediatric Pulmonology and Allergy Unit, Hôpital Jeanne de Flandre, CHRU de Lille and Université Nord de France, Lille, France.
Gunilla HedlinAstrid Lindgren Children's Hospital, Lung and Allergy Unit, Karolinska University Hospital, Stockholm, Sweden.
Elham HossnyPediatric Allergy and Immunology Unit, Children's Hospital Ain Shams University, Cairo, Egypt.
Peter Le SouëfSchool of Paediatrics and Faculty of Child Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia.
Paolo M MatricardiDepartment of Pediatric Pneumology & Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-5485-0324
Antonio NietoPediatric Pulmonology & Allergy Unit, Children's Hospital La Fe, Valencia, Spain.
Wanda PhipatanakulPediatric Allergy and Immunology, Boston Children's Hospital, Boston, Massachusetts.
Paulo M PitrezSchool of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Petr PohunekPediatric Department, 2nd Faculty of Medicine, Charles University Prague, and University Hospital Motol, Prague, Czech Republic.
Marcela GavornikovaNovartis Pharma AG, Basel, Switzerland.
Xavier JaumontNovartis Pharma AG, Basel, Switzerland.
David B PriceObservational and Pragmatic Research Institute, Singapore, Singapore.ORCID 0000-0002-9728-9992
Novartis (Switzerland) · CHAin Shams University Hospital · EGBoston Children's Hospital · USCentre Hospitalier Universitaire de Lille · FRCharité - Universitätsmedizin Berlin · DECharles University · CZImperial College London · GBKarolinska University Hospital · SELee University · USNational and Kapodistrian University of Athens · GRPontifícia Universidade Católica do Rio Grande do Sul · BRThe University of Western Australia · AUUniversity of Aberdeen · GBUniversity of Toronto · CA

Funding

Novartis Pharma AG, Basel, Switzerland
6 · The paper itself

Abstract

backgroundDespite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.

methodsA two-day, face-to-face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.

resultsThese unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.

conclusionsThere is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies may delay disease progression, leading to improved clinical outcomes.

Indexed as

Health Services Needs and DemandAdolescentAnti-Asthmatic AgentsAsthmaChildDelivery of Health CareGlucocorticoidsHumansOmalizumabPractice Guidelines as TopicUnited KingdomAnti-Asthmatic AgentsGlucocorticoidsOmalizumabasthma managementomalizumabpediatric asthmaunmet need

Identifiers

PMID30312503
PMCPMC7380053
OpenAlexW2897076429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.